Big Cap Biotech Worst and Best


28-Mar-2018 22:47 PM



     This March biotech sector stocks took a beating with iShares Nasdaq Biotech ETF (IBB) -3.74% performance. The top 10 weight for (IBB) dragged down entire sector.  Therefore, we going to take a look to see which of these big cap biotech have the best and worst performance based on the percentage off their 52 week high and low.

Here are the top 10 biotech in IBB holding 

  1. Celgene Corp (CELG:NASDAQ)
  2. Gilead Science Inc (GILD:NASDAQ)
  3. Biogen Inc (BIIB:NASDAQ)
  4. Amgen Inc (AMGN:NASDAQ)
  5. Regeneron Pharmaceuticals Inc (REGN:NASDAQ)
  6. Vertex Pharmaceuticals Inc (VRTX;NASDAQ)
  7. ILLumina Inc (ILMN:NASDAQ)
  8. Alexion Pharmaceuticals Inc (ALXN:NASDAQ)
  9. Incyte Corp (INCY:NASDAQ)
  10. Mylan NV (MYL:NASDAQ)

                                                                     These are data as of March 28,2018 closed.


     From the graph above, Incyte Corp (INCY:NASDAQ) have the worst percentage off their 52 week high, for the year performance it's down -39.09%, for the quarter down -10.94% and for the month it's down -1.86%. The best performance off their 52 week low is Vertex Pharmaceuticals Inc (VRTX:NASDAQ) with +78.86%, for the year to performance it's up +77.96%, quarter performance up +5.96% and month performance down -3.80%. 

     As can be seen, these big cap biotech stocks performance have a meaningful impact on the overall sector. How will these stock perform in April? Stay tuned.

Contact us:

Twitter: @BiotechMoney18




Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.